Physician profile
Todd Edward Bell
NPI 1093747156
$514.29
in general payments reported to CMS, 2019-2025
17 companies · $161 in 2025
The $161 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.46 · 2022: $62.67 · 2023: $103 · 2024: $111 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $374.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $79.65 | 2024-2025 | |
| Abbott Laboratories | $77.46 | 2019 | |
| Merck Sharp & Dohme LLC | $56.46 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Janssen Pharmaceuticals, INC | $38.77 | 2023-2024 | Xarelto |
| Medtronic, INC. | $27.70 | 2025 | Intellis Adaptivestim |
| Astellas Pharma US INC | $26.07 | 2025 | Veozah |
| Abbvie INC. | $24.34 | 2023 | Dalvance |
| Vapotherm INC | $22.46 | 2023 | Vapotherm |
| Astrazeneca Pharmaceuticals LP | $20.74 | 2025 | Breztri |
| Novo Nordisk INC | $20.37 | 2023 | Ozempic |
| Dexcom, INC. | $20.12 | 2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $19.24 | 2023 | Menveo, Bexsero |
| Mylan Specialty L.P. | $19.07 | 2022 | |
| Phathom Pharmaceuticals, INC. | $18.24 | 2025 | Voquezna |
| Ultragenyx Pharmaceutical INC. | $16.09 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $14.74 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.